Abstract
Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have